2. Search Result
Search Result
Results for "

Thrombolytic

" in MedChemExpress (MCE) Product Catalog:

9

Inhibitors & Agonists

5

Biochemical Assay Reagents

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-108865
    Alteplase

    Actilyse; Activase

    		 Others Cardiovascular Disease
    Alteplase (Actilyse; Activase), a tissue plasminogen activator prepared by recombination, is a thrombolytic agent that play important roles in acute ischemic stroke, pulmonary embolism, acute myocardial infarction, and occluded catheters .
    Alteplase
  • HY-E70230
    Staphylokinase, staphylococcus aureus

    SAK

    		 Others Cardiovascular Disease
    Staphylokinase, staphylococcus aureus (SAK) is a fibrin-specific plasminogen activator. Staphylokinase is an efficient, fibrin-selective thrombolytic agent .
    Staphylokinase, staphylococcus aureus
  • HY-122311
    Orniplabin

    SMTP-7

    		 Reactive Oxygen Species Neurological Disease Inflammation/Immunology
    Orniplabin (SMTP-7) is a low-molecular-weight compound that enhances plasminogen–fibrin binding, urokinase-catalyzed activation of plasminogen, and urokinase and plasminogen-mediated fibrin degradation. Orniplabin shows potential thrombolytic and anti-inflammatory effects. Orniplabin inhibits ROS .
    Orniplabin
  • HY-155909
    m-PEG-NHS ester (MW 3400)

    mPEG-SC (MW 3400); mPEG-Succinimidyl ester (MW 3400)

    		 Biochemical Assay Reagents Others
    m-PEG-NHS ester (MW 3400) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.
    m-PEG-NHS ester (MW 3400)
  • HY-155909A
    m-PEG-NHS ester (MW 1000)

    mPEG-SC (MW 1000); mPEG-Succinimidyl ester (MW 1000)

    		 Biochemical Assay Reagents Others
    m-PEG-NHS ester (MW 1000) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.
    m-PEG-NHS ester (MW 1000)
  • HY-155909B
    m-PEG-NHS ester (MW 550)

    mPEG-SC (MW 550); mPEG-Succinimidyl ester (MW 550)

    		 Biochemical Assay Reagents Others
    m-PEG-NHS ester (MW 550) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.
    m-PEG-NHS ester (MW 550)
  • HY-155909C
    m-PEG-NHS ester (MW 350)

    mPEG-SC (MW 350); mPEG-Succinimidyl ester (MW 350)

    		 Biochemical Assay Reagents Others
    m-PEG-NHS ester (MW 350) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.
    m-PEG-NHS ester (MW 350)
  • HY-W591424
    m-PEG-NHS ester (MW 2000)

    mPEG-SC (MW 2000); mPEG-Succinimidyl ester (MW 2000)

    		 Biochemical Assay Reagents Others
    m-PEG-NHS ester (MW 2000) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.
    m-PEG-NHS ester (MW 2000)
  • HY-157745
    m-PEG-NHS ester (MW 40000)

    mPEG-SC (MW 40000); mPEG-Succinimidyl ester (MW 40000)

    		 Biochemical Assay Reagents Others
    m-PEG-NHS ester (MW 40000) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects .
    m-PEG-NHS ester (MW 40000)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: